Cytokinetics, Incorporated (CYTK)
CYTK Stock Price Chart
Explore Cytokinetics, Incorporated interactive price chart. Choose custom timeframes to analyze CYTK price movements and trends.
CYTK Company Profile
Discover essential business fundamentals and corporate details for Cytokinetics, Incorporated (CYTK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
30 Apr 2004
Employees
498.00
Website
https://www.cytokinetics.comCEO
Robert I. Blum
Description
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
CYTK Financial Timeline
Browse a chronological timeline of Cytokinetics, Incorporated corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is -$1.59, while revenue estimate is $6.05M.
Earnings released on 7 Aug 2025
EPS came in at -$1.12 surpassing the estimated -$1.34 by +16.42%, while revenue for the quarter reached $66.77M , beating expectations by +3.13K%.
Earnings released on 6 May 2025
EPS came in at -$1.36 surpassing the estimated -$1.41 by +3.55%, while revenue for the quarter reached $1.58M , missing expectations by -43.36%.
Earnings released on 27 Feb 2025
EPS came in at -$1.26 surpassing the estimated -$1.29 by +2.33%, while revenue for the quarter reached $16.93M , beating expectations by +18.69%.
Earnings released on 6 Nov 2024
EPS came in at -$1.36 falling short of the estimated -$1.27 by -7.09%, while revenue for the quarter reached $463.00K , missing expectations by -77.41%.
Earnings released on 8 Aug 2024
EPS came in at -$1.31 falling short of the estimated -$1.02 by -28.43%, while revenue for the quarter reached $249.00K , missing expectations by -72.93%.
Earnings released on 8 May 2024
EPS came in at -$1.33 falling short of the estimated -$1.16 by -14.66%, while revenue for the quarter reached $835.00K , missing expectations by -7.22%.
Earnings released on 27 Feb 2024
EPS came in at -$1.38 falling short of the estimated -$1.03 by -33.98%, while revenue for the quarter reached $1.67M , missing expectations by -84.48%.
Earnings released on 2 Nov 2023
EPS came in at -$1.35 falling short of the estimated -$0.72 by -87.50%, while revenue for the quarter reached $378.00K , missing expectations by -96.59%.
Earnings released on 3 Aug 2023
EPS came in at -$1.34 falling short of the estimated -$1.23 by -8.94%, while revenue for the quarter reached $867.00K , missing expectations by -85.05%.
Earnings released on 4 May 2023
EPS came in at -$1.38 falling short of the estimated -$1.24 by -11.29%, while revenue for the quarter reached $4.61M , beating expectations by +120.72%.
Earnings released on 1 Mar 2023
EPS came in at -$1.45 falling short of the estimated -$1.22 by -18.85%, while revenue for the quarter reached $1.96M , missing expectations by -72.44%.
Earnings released on 3 Nov 2022
EPS came in at -$1.28 falling short of the estimated -$1.19 by -7.56%, while revenue for the quarter reached $2.52M , missing expectations by -28.29%.
Earnings released on 4 Aug 2022
EPS came in at -$0.23 surpassing the estimated -$1.04 by +77.88%, while revenue for the quarter reached $88.97M , beating expectations by +2.28K%.
Earnings released on 4 May 2022
EPS came in at -$1.02 falling short of the estimated -$0.93 by -9.68%, while revenue for the quarter reached $1.15M , missing expectations by -73.58%.
Earnings released on 24 Feb 2022
EPS came in at -$0.36 surpassing the estimated -$0.89 by +59.55%, while revenue for the quarter reached $55.60M , beating expectations by +858.41%.
Earnings released on 3 Nov 2021
EPS came in at -$0.95 falling short of the estimated -$0.75 by -26.67%, while revenue for the quarter reached $5.44M , missing expectations by -18.36%.
Earnings released on 5 Aug 2021
EPS came in at -$0.86 falling short of the estimated -$0.65 by -32.31%, while revenue for the quarter reached $2.84M , meeting expectations.
Earnings released on 6 May 2021
EPS came in at -$0.66 falling short of the estimated -$0.59 by -11.86%, while revenue for the quarter reached $6.55M , missing expectations by -3.99%.
Earnings released on 25 Feb 2021
EPS came in at -$0.62 falling short of the estimated -$0.48 by -29.17%, while revenue for the quarter reached $6.72M , beating expectations by +19.72%.
Earnings released on 4 Nov 2020
EPS came in at -$0.05 surpassing the estimated -$0.59 by +91.53%, while revenue for the quarter reached $41.69M , missing expectations by -82.11%.
CYTK Stock Performance
Access detailed CYTK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.